PARIS--(BUSINESS WIRE)--MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces that data from its first pivotal Phase III study with MD1003 (a highly-concentrated pharmaceutical-grade biotin) for the treatment of primary and secondary progressive multiple sclerosis, will be presented at the Clinical Trials Plenary Session at The American Academy of Neurology (AAN) Annual Meeting, Washington DC on Friday April 24th at 1200 EST.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.